Precision Wealth Strategies LLC Invests $152,000 in ProPhase Labs, Inc. (NASDAQ:PRPH)

Precision Wealth Strategies LLC acquired a new position in shares of ProPhase Labs, Inc. (NASDAQ:PRPHGet Rating) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,495 shares of the company’s stock, valued at approximately $152,000. Precision Wealth Strategies LLC owned about 0.07% of ProPhase Labs as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in ProPhase Labs by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 512,609 shares of the company’s stock worth $3,588,000 after acquiring an additional 14,671 shares during the last quarter. Avidian Wealth Solutions LLC grew its holdings in ProPhase Labs by 17.2% during the 1st quarter. Avidian Wealth Solutions LLC now owns 140,342 shares of the company’s stock worth $982,000 after acquiring an additional 20,588 shares during the last quarter. State Street Corp grew its holdings in ProPhase Labs by 14.2% during the 1st quarter. State Street Corp now owns 31,063 shares of the company’s stock worth $217,000 after acquiring an additional 3,868 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in ProPhase Labs during the 2nd quarter worth about $168,000. Institutional investors own 9.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. TheStreet lowered shares of ProPhase Labs from a “b” rating to a “c+” rating in a research note on Tuesday, August 23rd. StockNews.com lowered shares of ProPhase Labs from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 30th. Finally, Dawson James lowered shares of ProPhase Labs from a “neutral” rating to a “sell” rating in a research note on Thursday, July 21st.

ProPhase Labs Stock Performance

Shares of NASDAQ:PRPH opened at $10.26 on Friday. The company has a market capitalization of $164.26 million, a price-to-earnings ratio of 6.84 and a beta of -0.40. The firm’s 50 day simple moving average is $11.33 and its 200 day simple moving average is $9.77. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.20 and a quick ratio of 3.93. ProPhase Labs, Inc. has a fifty-two week low of $4.90 and a fifty-two week high of $15.25.

ProPhase Labs Company Profile

(Get Rating)

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

Read More

Institutional Ownership by Quarter for ProPhase Labs (NASDAQ:PRPH)

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.